Geron Corp
0.00 (0.00%)


Draw Mode:

Volume 120
Bid Price 2.22
Ask Price 2.52
News -
Day High


52 Week Range


Day Low
Company Name Stock Ticker Symbol Market Type
Geron Corp GERN NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.00 0.0% 2.30 04:37:04
Open Price Low Price High Price Close Price Prev Close
Trades Volume Avg Volume 52 Week Range
2 120 - 1.17 - 3.84
Last Trade Time Type Quantity Stock Price Currency
04:27:12 70 $ 2.25 USD

Geron Corp Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 1.17B 508.72M 506.44M $ 596.00k $ - -0.37 179.90
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - 8.99k 1.20%

more financials information »

Geron News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No GERN Message Board. Create One! See More Posts on GERN Message Board See More Message Board Posts

Historical GERN Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week2.662.712.252.489,397,189-0.36-13.53%
1 Month2.862.932.252.635,558,560-0.56-19.58%
3 Months2.083.842.0452.919,363,4040.2210.58%
6 Months2.433.841.962.706,405,600-0.13-5.35%
1 Year1.243.841.172.434,820,5131.0685.48%
3 Years1.023.840.951.983,843,4491.28125.49%
5 Years5.446.990.752.343,745,547-3.14-57.72%

Geron Description

Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's leading drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses global rights to this drug.